Hoth Therapeutics Inc

HOTH

Company Profile

  • Business description

    Hoth Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing new-generation therapies for unmet medical needs. It is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT); and a treatment and/or prevention for Alzheimer’s or other neuroinflammatory diseases (HT-ALZ). The company also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004); and an obesity treatment, and obesity-related diseases and conditions (HT-VA).

  • Contact

    1177 Avenue of the Americas
    5th Floor, Suite 5066
    New YorkNY10036
    USA

    T: +1 646 756-2997

    https://www.hoththerapeutics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    3

Stocks News & Analysis

stocks

Navigating the ASX dividend landscape in 2026

Dividend yields are well below the 10-year average. Here’s how to navigate lower yields in 2026.
stocks

Meta stock has struggled amid AI spending concerns. Is it a buy?

Meta stock has lost ground as investors raise concern over capital expenditures and risky AI strategies.
stocks

Netflix Earnings: Strong, as expected; 2026 guidance confirms decelerating growth

We think Netflix stock is moderately overvalued.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,174.2014.100.15%
CAC 408,148.8979.720.99%
DAX 4024,856.47295.491.20%
Dow JONES (US)49,384.01306.780.63%
FTSE 10010,150.0511.960.12%
HKSE26,629.9644.900.17%
NASDAQ23,436.02211.200.91%
Nikkei 22553,688.89914.251.73%
NZX 50 Index13,507.7149.16-0.36%
S&P 5006,913.3537.730.55%
S&P/ASX 2008,845.109.200.10%
SSE Composite Index4,122.585.640.14%

Market Movers